Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)
-
F. Couñago [7] ; A. Rodríguez [1] ; P. Calvo [5] ; J. Luna [2] ; J. L. Monroy [6] ; B. Taboada [5] ; V. Díaz [3] ; N. Rodríguez de Dios [4]
-
[1] Hospital Ruber Internacional
Hospital Ruber Internacional
Madrid, España
-
[2] Fundación Jiménez Díaz
Fundación Jiménez Díaz
Madrid, España
-
[3] Hospital Universitario Puerta del Mar
Hospital Universitario Puerta del Mar
Cádiz, España
-
[4] Hospital de la Esperanza
Hospital de la Esperanza
Barcelona, España
-
[5] Hospital Universitario Santiago de Compostela, España
-
[6] Hospital Universitario La Ribera, España
-
[7] Hospital Universitario Quirón, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 1 (January 2017), 2017, págs. 31-43
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
In recent years, major advances in our understanding of the molecular biology of lung cancer, together with significant improvements in radiotherapy technologies, have revolutionized the treatment of non-small cell lung cancer (NSCLC). This has led to the development of new therapies that target molecular mutations specific to each tumor type, acting on the cell surface antigens or intracellular signaling pathways, or directly affecting cell survival. At the same time, ablative dose radiotherapy can be delivered safely in the context of metastatic disease. In this article, the GOECP/SEOR (Oncological Group for Study of Lung Cancer/Spanish Society of Radiation Oncology) reviews the role of new targeted therapies used in combination with radiotherapy in patients with locally advanced (stage III) NSCLC and in patients with advanced, metastatic (stage IV) NSCLC.
